Evidence map›Paper›PMID 35464479›Full record

ArticleFrontiers in immunology2022

Case Report: Precision COVID-19 Immunization Strategy to Overcome Individual Fragility: A Case of Generalized Lipodystrophy Type 4.

Salvatore Zaffina, Eva Piano Mortari, Reparata Rosa Di Prinzio, Marco Cappa, Antonio Novelli, Emanuele Agolini, Massimiliano Raponi, Bruno Dallapiccola, Franco Locatelli, Carlo Federico Perno and 1 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. A new mutation in theFrontiers in endocrinology · 2023
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Salvatore ZaffinaOccupational Medicine/Health Technology Assessment and Safety Research Unit, Clinical-Technological Innovations Research Area, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Eva Piano MortariDiagnostic Immunology Research Unit, Multimodal Medicine Research Area, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Reparata Rosa Di PrinzioOccupational Medicine/Health Technology Assessment and Safety Research Unit, Clinical-Technological Innovations Research Area, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Marco CappaUnit of Endocrinology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Antonio NovelliLaboratory of Medical Genetics, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Emanuele AgoliniLaboratory of Medical Genetics, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Massimiliano RaponiMedical Direction, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Bruno DallapiccolaGenetics and Rare Diseases Research Division, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Franco LocatelliDepartment of Pediatric Hematology and Oncology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Carlo Federico PernoMicrobiology and Diagnostic Immunology Unit and Multimodal Medicine Research Area, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Rita CarsettiDiagnostic Immunology Research Unit, Multimodal Medicine Research Area, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Bambino Gesù Children's Hospital · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 48-year-old patient affected with congenital generalized lipodystrophy type 4 failed to respond to two doses of the BNT162b2 vaccine, consisting of lipid nanoparticle encapsulated mRNA. As the disease is caused by biallelic variants of

Indexed as

Adenovirus VaccinesCOVID-19Lipodystrophy, Congenital GeneralizedBNT162 VaccineCOVID-19 VaccinesHumansLiposomesMiddle AgedNanoparticlesSARS-CoV-2VaccinationAdenovirus VaccinesBNT162 VaccineCOVID-19 VaccinesLipid NanoparticlesLiposomescase reportCAVIN1congenital generalized lipodystrophy type 4memory B cellsSARS-CoV-2 vaccine

Identifiers

PMID35464479
PMCPMC9020769
OpenAlexW4224269830

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.